[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
作者信息
Amato L, Nava L, Rizzo M, Piccoli F
出版信息
Riv Neurol. 1985 Jan-Feb;55(1):46-52.
PMID:3927468
Abstract
摘要
相似文献
1
2
Selegiline for Parkinson's disease.司来吉兰用于帕金森病。
Am Fam Physician. 1990 Feb;41(2):589-91.
3
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.司来吉兰治疗帕金森病。一种特定的B型单胺氧化酶抑制剂。
N Y State J Med. 1984 Jan;84(1):13-6.
4
Deprenyl and levodopa and Parkinson's disease progression.司来吉兰、左旋多巴与帕金森病进展
Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228.
5
[Optimization of the treatment of Parkinson's disease using dopamine agonists].[使用多巴胺激动剂优化帕金森病治疗]
Arch Neurobiol (Madr). 1991 Nov-Dec;54(6):282-7.
6
Selegiline: a second look. Six years later: too risky in Parkinson's disease.司来吉兰：再审视。六年后：对帕金森病风险过高。
Prescrire Int. 2002 Aug;11(60):108-11.
7
Pergolide and selegiline for Parkinson's disease.培高利特和司来吉兰用于治疗帕金森病。
Med Lett Drugs Ther. 1989 Sep 8;31(800):81-3.
8
(-)Deprenyl in the treatment of Parkinson's disease.（-）司来吉兰治疗帕金森病。
Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004.
9
Deprenyl in Parkinson's disease.司来吉兰与帕金森病
Lancet. 1982 Sep 25;2(8300):695-6.
10
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.帕金森病治疗的最新进展：单胺氧化酶抑制剂的应用
Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811.
Zotero 插件